Focal low-dose rate brachytherapy for the treatment of prostate cancer.
Whole-gland low-dose rate (LDR) brachytherapy has been a well-established modality of treating low-risk prostate cancer. Treatment in a focal manner has the advantages of reduced toxicity to surrounding organs. Focal treatment using LDR brachytherapy has been relatively unexplored, but it may offer advantages over other modalities that have established experiences with a focal approach. This is particularly true as prostate cancer is being detected at an earlier and more localized stage with the advent of better detection methods and newer imaging modalities.
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
William Y
WY
Tong
Gilad
G
Cohen
Yoshiya
Y
Yamada
brachytherapy; focal; low dose rate; prostate cancer